Background: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying anti-rheumatic drugs (DMARD) about half of RA patients reach the disease remission state (1), raising the question about tapering or stopping anti-rheumatic treatment and appropriate predictors (2). Objectives: To analyse the effect of a risk-stratified DMARD tapering algorithm based on multiple-biomarker disease activity (MBDA) score and anti-citrullinated protein (ACPA) status for successful DMARD tapering and treatment cost reduction in RA patients in sustained remission enrolled in the prospective randomized controlled RETRO study (3,4). Methods: MBDA scores and ACPA status were determined in the baseline samples of 146 patients in sustained remission. Patients either continued DMARDs (arm1), tapered dose by 50% (arm 2) or stopped DMARDs after tapering (arm 3) for one year according to the RETRO study protocol. Direct treatment costs (including testing costs at baseline) were evaluated every three months. MBDA and ACPA status were used as predictors creating a risk-stratified tapering algorithm based on relapse rates. Results: RA patients with a low MBDA score (<30) and negative ACPA showed lowest relapse risk (19%). With either single positivity for ACPA or moderate/high MBDA scores (≥30) relapse risk increased and was high in double-positive patients (61%). In MBDA negative (<30) and MBDA single-positive (≥30) groups, DMARD tapering appears feasible. Considering only patients that did not flare, costs for synthetic and biologic DMARDs in the MBDA-negative and singlepositive groups (n=41) would have been 123.751,29 for full-dose treatment over one year. Tapering and stopping DMARDs in this low-risk relapse groups allowed a reduction of 92.821,50 (-75%) of DMARD costs. Average reduction of DMARD costs per patient were 2.350,08 in the double negative (MBDA-/ACPA-) and single negative (MBDA-/ACPA+) group and 1.761,43 in the MBDA single positive (MBDA+ /ACPA-) group.
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Conclusions:
Combining MBDA score and ACPA status allows risk stratification for successful DMARD tapering and cost-effective use of biologic DMARD. Given that previous data of the RETRO have shown that patients relapsing after tapering their DMARDs respond well to their reintroduction, a stratified tapering and stopping of DMARDs is not only a cost economic but also clinically feasible strategy. Background: Making the earliest diagnosis of rheumatoid arthritis (RA) is crucial to initiate treatment and prevent further disease progression and joint damage. Despite recent advances with the discovery and integration of anti-cyclic citrullinated protein antibody (ACPA) in classification criteria, there is still an unmet need for new diagnostic biomarkers, notably for ACPA-negative disease. Power Doppler ultrasound has been shown to identify poor prognosis disease in ACPA negative patients. Objectives: The receptor-activator-nuclear-factor-κB axis (RANK/RANKL) is known to regulate bone homeostasis. The aim of this pilot study is to establish whether serum RANKL levels in people with early inflammatory arthritis are associated with RA diagnosis at follow-up and to evaluate the added value of RANKL with ultrasound for early RA diagnosis. Methods: Serum from 298 subjects (95/204 Male/Female) was collected at the baseline participant visit to the Leeds Early Arthritis clinic. Demographic (age, gender symptom duration) and clinical data (swollen and tender joint counts (SJC, TJC), CRP, DAS28, rheumatoid factor (RF) and ACPA, shared epitope (SE)) were collected. A commercial ELISA (BioVENDOR) was used to measure RANKL. Ultrasound of 26 joints (bilateral elbows, wrists, MCP 2-3, PIP 2-3, knees, ankles and MTP 1-5) was performed at baseline recording summative scores for power Doppler (PD), grey scale hypertrophy (GS) and erosions (ERO). Results: At 1 year follow-up, 151 patients had a confirmed diagnosis of RA (EULAR 2010 criteria) and 147 were classified as non-RA (undifferentiated arthritis, other inflammatory diagnoses or non-persistent inflammation). All routinely used biomarkers were associated with RA diagnosis (ACPA, RF, SE, TJC, SJC, CRP, DAS28, p<0.0001), as were imaging biomarkers (PD, GS, ERO, p<0.001). RANKL levels were significantly higher in RA (RA 1002.4±1053.2pmol/L, non-RA 339.2±451.5pmol/L, p<0.0001). A regression analysis suggested that four parameters were sufficient to account for all associations with RA: RANKL, age, SJC, and PD with 75.3% accurate prediction. An AUROC analysis suggested a cut-off for each parameter and a score was calculated, adding 1 point for each of the factors (RANKL>700, age>62, TPD>3, SJC>4). This score predicted RA with an AUROC of 0.782 ((0.23-0.840), p<0.0001). The same analysis repeated for ACPA negative patients only (n=193) showed similar results, providing accurate diagnosis of RA (77.6% correct by regression) and with an AUROC of 0.774 ((0.690-0.858), p<0.0001). Conclusions: A score incorporating RANKL, age, SJC and PD showed good predictive value for non-RA when low and for RA when high. Furthermore, the analysis redone in ACPA-negative patients performed particularly well for predicting RA with a good AUROC value. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.3226 
